# OnCo record dlbcl (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/dlbcl/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "dlbcl" ;
  schema:name "Diffuse large B-cell lymphoma"@en ;
  schema:description "Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."@en ;
  schema:url <https://onco.cc/cancers/dlbcl/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Diffuse_large_B-cell_lymphoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q2626074> ;
  schema:citation <https://en.wikipedia.org/wiki/Diffuse_large_B-cell_lymphoma> ;
  onco:tag "heme", "spike" ;
  onco:related <https://onco.cc/pairings/car-t-before-transplant-lbcl/>, <https://onco.cc/pairings/bispecific-plus-adc-lymphoma/>, <https://onco.cc/collections/lymphoma-research-foundation/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>, <https://onco.cc/cancers/burkitt-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/primary-cns-lymphoma/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/fdg-pet/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd3/>, <https://onco.cc/targets/ror1/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/ezh2/>, <https://onco.cc/targets/cd47/> ;
  onco:drugs <https://onco.cc/drugs/clonoseq/>, <https://onco.cc/drugs/carmustine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/palifermin/>, <https://onco.cc/drugs/rasburicase/> ;
  onco:companies <https://onco.cc/companies/marker-therapeutics/>, <https://onco.cc/companies/ranok-therapeutics-hangzhou/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/genmab/>, <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/gilead/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/incyte/>, <https://onco.cc/companies/regeneron/>, <https://onco.cc/companies/adc-therapeutics/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/foresight-diagnostics/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/md-anderson/>, <https://onco.cc/institutions/dana-farber/>, <https://onco.cc/institutions/mayo-clinic/>, <https://onco.cc/institutions/gustave-roussy/>, <https://onco.cc/institutions/the-christie/> ;
  onco:pathways <https://onco.cc/pathways/apoptosis-bcl2/> ;
  onco:terms <https://onco.cc/terms/ipi-score/>, <https://onco.cc/terms/cell-of-origin/>, <https://onco.cc/terms/double-hit-lymphoma/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/> ;
  onco:trials <https://onco.cc/trials/nct07011056/>, <https://onco.cc/trials/nct07570823/>, <https://onco.cc/trials/nct06929624/>, <https://onco.cc/trials/nct07409428/>, <https://onco.cc/trials/nct07188558/>, <https://onco.cc/trials/nct07215585/>, <https://onco.cc/trials/nct06792253/>, <https://onco.cc/trials/nct04442022/>, <https://onco.cc/trials/nct04529772/>, <https://onco.cc/trials/nct04094311/>, <https://onco.cc/trials/nct06717347/>, <https://onco.cc/trials/nct07226752/>, <https://onco.cc/trials/nct04384484/>, <https://onco.cc/trials/nct05429268/>, <https://onco.cc/trials/nct06508658/>, <https://onco.cc/trials/nct01804686/>, <https://onco.cc/trials/nct06091865/>, <https://onco.cc/trials/nct04404283/>, <https://onco.cc/trials/l-mind/>, <https://onco.cc/trials/zuma-1/> ;
  onco:journals <https://onco.cc/journals/blood-cancer-discovery/>, <https://onco.cc/journals/blood-cancer-journal/>, <https://onco.cc/journals/clinical-lymphoma-myeloma-and-leukemia/>, <https://onco.cc/journals/current-hematologic-malignancy-reports/>, <https://onco.cc/journals/haematologica/>, <https://onco.cc/journals/hematological-oncology/>, <https://onco.cc/journals/leukemia-and-lymphoma/> ;
  onco:pipeline <https://onco.cc/drugs/zilovertamab-vedotin/>, <https://onco.cc/drugs/abexinostat/>, <https://onco.cc/drugs/dzd8586/>, <https://onco.cc/drugs/rocbrutinib/>, <https://onco.cc/drugs/mk-1045/>, <https://onco.cc/drugs/purinostat/>, <https://onco.cc/drugs/sctb35/>, <https://onco.cc/drugs/shr-a1912/>, <https://onco.cc/drugs/hmpl-760/>, <https://onco.cc/drugs/rondecabtagene-autoleucel/>, <https://onco.cc/drugs/azd0486/>, <https://onco.cc/drugs/ifupinostat/>, <https://onco.cc/drugs/tqb2825/>, <https://onco.cc/drugs/krt-232/>, <https://onco.cc/drugs/zamtocabtagene-autoleucel/>, <https://onco.cc/drugs/tc011/>, <https://onco.cc/drugs/crc01/>, <https://onco.cc/drugs/jnj-90014496/>, <https://onco.cc/drugs/ctx112/>, <https://onco.cc/drugs/allo-647/>, <https://onco.cc/trials/frontmind/>, <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/trials/epcore-dlbcl-2/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/golcadomide/>, <https://onco.cc/trials/golseek-1/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/trials/sunmo/>, <https://onco.cc/drugs/odronextamab/>, <https://onco.cc/trials/waveline-003/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/>, <https://onco.cc/ideas/idea-ctdna-guided-dlbcl-frontline/>, <https://onco.cc/ideas/idea-bispecific-vs-car-t-second-line/> ;
  onco:standardOfCare <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/zynlonta/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/polatuzumab-vedotin/>, <https://onco.cc/terms/ipi-score/>, <https://onco.cc/trials/polarix/>, <https://onco.cc/drugs/polatuzumab-vedotin/>, <https://onco.cc/trials/frontmind/>, <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/terms/double-hit-lymphoma/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/trials/zuma-7/>, <https://onco.cc/trials/transform/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/polatuzumab-vedotin/>, <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/drugs/zynlonta/>, <https://onco.cc/trials/sunmo/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/zynlonta/>, <https://onco.cc/drugs/zilovertamab-vedotin/>, <https://onco.cc/trials/waveline-003/> .